Diabetes mellitus, type 2, diabetic polyneuropathy, trigeminal neuralgia.

Patient Profile and Chief Complaints

• Severe, acute right-sided facial pain, highly characteristic of an acute trigeminal neuralgia flare-up.
• Persistent pain and paresthesia (numbness, “pins and needles” sensation) in the lower extremities, indicative of progressive diabetic polyneuropathy.
• Poorly controlled glycemia, with blood glucose levels consistently remaining at  8–9 mmol/L despite ongoing standard therapy.

Fig.1. Trigeminal nerve (second branch) peripheral block with allogenic umbilical cord derived stem cells.

Initial Assessment and Neurological Status

Prior to initiating cell therapy, the patient underwent a comprehensive baseline evaluation to establish clinical benchmarks:

• General Condition: Conscious and fully oriented. Glasgow Coma Scale (GCS) score = 15/15.
• Deep Tendon Reflexes: Normal and symmetric in both upper and lower extremities ().
• Motor Strength: Upper extremities scored 5/5 on the MRC scale (normal); lower extremities demonstrated a reduction to 4/5 on the MRC scale due to neuropathic complications.
• Pain Intensity: Evaluated at 8/10 on the Visual Analog Scale (VAS), reflecting severe, debilitating pain.
• Brain MRI: Demonstrated no structural pathology or organic abnormalities that could account for mechanical nerve compression.

Treatment Protocol: Regenerative Cell Therapy (QR Clinic)

Following a multidisciplinary medical board review, umbilical cord-derived mesenchymal stem cells (UC-MSCs) were prescribed as an adjunctive treatment. The clinical protocol combined two delivery routes:

Systemic Therapy: Intravenous (IV) infusion of allogeneic umbilical cord-derived mesenchymal stem cells (MSCs). This was aimed at inducing a systemic anti-inflammatory response, improving microcirculation, and promoting the regeneration of pancreatic beta-cells to address type 2 diabetes.

Local Therapy: A peripheral nerve block of the second division (V2) of the trigeminal nerve, combined with the local administration of allogeneic umbilical cord-derived stem cells. This targeted direct myelin sheath repair, the alleviation of localized neuroinflammation, and rapid pain relief.

Treatment Outcomes and Clinical Course (4-Month Follow-Up)

At the 4-month follow-up assessment, the patient exhibited significant clinical improvement across all key parameters:

• Pain Reduction: The VAS pain score decreased dramatically from 8 to 3. Trigeminal neuralgia attacks became substantially less frequent and far less intense.
• Improved Glycemic Control: Fasting blood glucose levels stabilized within the range of 6–7 mmol/L (compared to baseline levels of  8–9 mmol/L), indicating enhanced peripheral insulin sensitivity.
• Neurological Recovery: The patient reported a marked reduction in lower extremity discomfort. Motor strength in the lower limbs returned to a normal 5/5 on the MRC scale. Her GCS score remained stable at 15.

Ongoing Recommendations and Long-Term Monitoring

The patient received personalized lifestyle guidance and supportive therapy recommendations. To track the long-term efficacy and durability of this regenerative treatment, the protocol dictates mandatory follow-up evaluations at 6 and 12 months post-procedure.

Frequently Asked Questions: Stem Cell Therapy for Type 2 Diabetes

Can stem cell therapy completely cure type 2 diabetes?

Currently, regenerative medicine does not offer a permanent, absolute cure for type 2 diabetes. However, clinical studies demonstrate that the administration of mesenchymal stem cells (MSCs) can induce long-term clinical and laboratory remission. This is characterized by a sustained reduction in glycated hemoglobin (HbA1c) levels, a decreased reliance on oral hypoglycemic agents or insulin, and a halt in the progression of diabetic complications, such as neuropathy or retinopathy.

How exactly do stem cells help manage type 2 diabetes?

In type 2 diabetes, stem cells exert their therapeutic effects through three primary mechanisms:

• Addressing Insulin Resistance: MSCs secrete specific anti-inflammatory cytokines that reduce chronic low-grade systemic inflammation, thereby restoring tissue receptor sensitivity to endogenous insulin.
• Pancreatic Beta-Cell Protection: The therapy promotes the survival, function, and regeneration of insulin-producing -cells within the islets of Langerhans, shielding them from progressive autoimmune or metabolic destruction.
• Vascular and Neural Repair: MSCs stimulate angiogenesis (the formation of new capillaries), which enhances microcirculation and aids in the repair of damaged peripheral nerve fibers.

Which types of stem cells are considered the safest and most effective?

Under international clinical guidelines, the gold standard for therapeutic efficacy and safety is umbilical cord-derived mesenchymal stem cells (UC-MSCs), alongside adipose- or bone marrow-derived MSCs. Umbilical cord tissue cells possess the highest proliferative and regenerative potential. Crucially, they are immunoprivileged, meaning they do not trigger an immune response or host rejection, making the procedure exceptionally safe.

Clinical Research and Key Studies

• Study in Stem Cell Research & Therapy: Multi-center clinical trials have demonstrated that the systemic administration of UC-MSCs in type 2 diabetic patients significantly improves beta-cell function and lowers HbA1c levels over a 12-to-24-month observation period with an excellent safety profile.
• Meta-Analysis in Frontiers in Endocrinology: A systematic review of dozens of clinical trials confirms that MSC therapy is highly safe and yields the most robust clinical outcomes when initiated while the patient’s pancreas still retains residual insulin secretory capacity.